AbbVie entered into a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion in cash to significantly expand and strengthen its world-class immunology portfolio. This strategic acquisition allows AbbVie to gain control of Apogee's highly promising, differentiated pipeline of advanced antibody therapies—such as zumilokibart—designed to treat atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other major immunological conditions with optimized dosing intervals.